Cyclotek was established in 2001, to be an efficient and reliable supplier of quality PET Radiopharmaceuticals (tracers) for the Australian and New Zealand market.
Cyclotek operates two cyclotrons at it’s main facility in Bundoora, Victoria, Australia. The first GE PETtrace Cyclotron was installed in 2002 and has been the mainstay of commercial production of FDG for PET Clinical Service Providers in Australia and New Zealand. A second cyclotron was installed in 2006, to provide additional capacity for production, redundancy and R&D. In keeping with the growth of the New Zealand market, a facility was established in Wellington, New Zealand, with our joint venture partners, Pacific Radiology Group, and has been in operation since 2010.
Two new facilities commenced construction during 2015, one at the Victorian Comprehensive Cancer Centre (VCCC) in Melbourne and the other at the Princess Alexandra Hospital in Brisbane. The Princess Alexandra Hospital facility was completed in December 2015 and achieved TGA & Queensland Health approval in May 2016 and is now actively supplying customers in Queensland and Northern New South Wales. The VCCC facility gained TGA approval in February 2018 and will complement the activities of our Bundoora facility supporting customers within Victoria, Tasmania and back-up supply within the group.
Until now, PET scanning has mainly relied on 18-Fludeoxyglucose (FDG), a tracer that targets upregulated metabolic activity. FDG has therefore been the main product produced by Cyclotek, since commencement of operations in 2002.
Since 2007, Cyclotek has been involved in development of novel PET tracers. We currently produce eight Investigational Medicinal Products (IMPs) for research and clinical trials, including a number of proprietary tracers under contract to pharmaceutical companies.
Our facilities are licensed by the Therapeutic Goods Administration (TGA) to manufacture and distribute products throughout Australia, and by the Ministry of Health in New Zealand. Licensing is primarily based on compliance with the Code of Good Manufacturing Practice (GMP).
The company is well placed to develop and expand its operational capacity and to introduce additional Investigational Medicinal Products.